EUVIMEDEUVIMED entdecken
Crossref

Review of dermatofibrosarcoma protuberans

Su X Lim, Arjun Ramaiya, Nick J Levell iD, Zoe C Venables

Clinical and Experimental Dermatology · 22.03.2023 · 48 (4) · 297-302

DOI: 10.1093/ced/llac111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 10.12.2022. Verfasst von Su X Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology and Norfolk and Norwich University Hospital, Norwich, UK. Hauptthemen laut MEDLINE: Dermatofibrosarcoma, Skin Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical features, histological subtypes and management of dermatofibrosarcoma protuberans (DFSP) are reviewed in this article. DFSP is an uncommon cutaneous sarcoma first described in 1890. It has a high local recurrence rate, low metastatic rate and low mortality. The crude incidence rate in England in 2019 was reported as 3.0 per million person-years. A fusion of platelet-derived growth factor subunit B (PDGFB) and COL1A1, t(17;22)(q22;q13), has been found in over 90% of people with DFSP. This fusion is thought to upregulate PDGFB expression, stimulating cell growth by activation of Ras mitogen-activated protein kinases and PI3K–AKT–mTOR, potentiating oncogenesis. DFSP usually presents as an asymptomatic flesh-coloured, thickened, rubbery plaque or nodule with an uneven surface. The most common sites are the trunk followed by lower limbs, head and neck and upper limbs. Larger tumours can infiltrate underlying local structures and around 1% metastasize. Key histological features in DFSP are spindle cells arranged in a storiform pattern with intense CD34 staining. Histological subtypes include classical DFSP, Bednar, myxoid, giant cell fibroblastoma, atrophic and DFSP–fibrosarcomatous. The gold standard management for localized tumours is surgical: current recommendations favour Mohs micrographic surgery over wide local excision. Adjuvant radiotherapy may be offered after surgery. Imatinib can be used as neoadjuvant therapy and in patients with inoperable or metastatic tumours. Further research should be conducted to better understand pathogenesis of DFSP, identify associated risk factors and standardize management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatofibrosarcomaSkin NeoplasmsHumansProto-Oncogene Proteins c-sisPhosphatidylinositol 3-KinasesImatinib MesylateMohs Surgery

Substanzen

Proto-Oncogene Proteins c-sisPhosphatidylinositol 3-KinasesImatinib Mesylate

Autor:innen und Institutionen

  • Departments of Dermatology and Norfolk and Norwich University Hospital, Norwich, UK.
  • Departments of Histopathology, Norfolk and Norwich University Hospital, Norwich, UK.
  • University of East Anglia Norwich Medical School, Norwich, UK.
  • National Disease Registration Service, NHS Digital, Leeds, UK.

ORCID-Profile: Nick J Levell

Zitieren

APA

Lim, S. X., Ramaiya, A., Levell, N. J., & Venables, Z. C. (2023). Review of dermatofibrosarcoma protuberans. Clinical and Experimental Dermatology, 48(4), 297-302. https://doi.org/10.1093/ced/llac111

Vancouver

Lim SX, Ramaiya A, Levell NJ, Venables ZC. Review of dermatofibrosarcoma protuberans. Clinical and Experimental Dermatology. 2023;48(4):297-302. doi:10.1093/ced/llac111

BibTeX
@article{Lim2023,
  author = {Lim, Su X and Ramaiya, Arjun and Levell, Nick J and Venables, Zoe C},
  title = {Review of dermatofibrosarcoma protuberans},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  volume = {48},
  number = {4},
  pages = {297--302},
  doi = {10.1093/ced/llac111}
}
Kostenlos starten →